But with the stock down 45% from its 52-week high, Novo Nordisk could be a strong turnaround opportunity in the GLP-1 space, given the long-term growth potential of GLP-1 drugs
Antibody development was not associated with decreased effectiveness, but it was associated with an increase in hypersensitivity and injection site reactions (6.2% and 11.3%, respectively)
As industry leaders such as Novo Nordisk and Eli Lilly drive this evolution, GlobalData anticipates a reorientation in drug preferences in the coming years. For a March 2024 article about Ozempic babies, click here.
Carnitor 6
, (nitric oxide) , endothelin-1 , (reactive oxygen species) ,
Stability testing should demonstrate shelf life of at least 24 months with preserved peptide activity